Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $250.68 --0%
EPS Growth %: -20.4%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -20.4%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.30, $0.53 better than the analyst estimate of $4.77. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $19.20-$20.30, versus the consensus of $18.51. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.05 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
- UBS Downgrades AREIT Inc (AREIT:PM) to Neutral
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
